生物标志物联合影像学在肺结节诊断中的研究进展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

张珂煜 ¹ , 邵栋 ^1,2 , 赵亚昆 ^1,2 ,  田燕歌 ^1,3

1. ;
2. ;
3. ;

Corresponding author：

田燕歌, Email: yange0910@126.com

Keywords：

DOI：

10.7507/1671-6205.202405056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 张珂煜, 邵栋, 赵亚昆, 田燕歌. 生物标志物联合影像学在肺结节诊断中的研究进展. Chinese Journal of Respiratory and Critical Care Medicine, 2025, 24(2): 128-134. doi: 10.7507/1671-6205.202405056 Copy

1.	中华医学会呼吸病学分会肺癌学组, 中国肺癌防治联盟专家组. 肺结节诊治中国专家共识(2018年版). 中华结核和呼吸杂志, 2018, 41(10): 763-771.
2.	Liang X, Kong Y, Shang H, et al. Computed tomography findings, associated factors, and management of pulmonary nodules in 54, 326 healthy individuals. J Cancer Res Ther, 2022, 18(7): 2041-2048.
3.	谭双平, 张彤, 祖江林, 等. 深度学习驱动的CT影像肺结节检测: 挑战、进展和展望. 中国医疗器械杂志, 2023, 47(2): 163-172.
4.	Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood), 2018, 243(3): 213-221.
5.	Shen C, Wu Q, Xia Q, et al. Establishment of a malignancy and benignancy prediction model of sub-centimeter pulmonary ground-glass nodules based on the inflammation-cancer transformation theory. Front Med (Lausanne), 2022, 9: 1007589.
6.	Husari A, Hashem Y, Zaatari G, et al. Pomegranate juice prevents the formation of lung nodules secondary to chronic cigarette smoke exposure in an animal model. Oxid Med Cell Longev, 2017, 2017: 6063201.
7.	Zhang Y, Liu Y, Wang J, et al. Atractylenolide II inhibits tumor-associated macrophages (TAMs)-induced lung cancer cell metastasis. Immunopharmacol Immunotoxicol, 2022, 44(2): 227-237.
8.	Tian T, Lu J, Zhao W, et al. Associations of systemic inflammation markers with identification of pulmonary nodule and incident lung cancer in Chinese population. Cancer Med, 2022, 11(12): 2482-2491.
9.	姜文军. 血清中IL-15、IL-6、TNF-β、IFN-γ、CRP、Beclin1与早期肺腺癌关系的研究. 安徽医科大学, 2022.
10.	Daly S, Rinewalt D, Fhied C, et al. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol, 2013, 8(1): 31-36.
11.	Liu CY, Xie WG, Wu S, et al. A comparative study on inflammatory factors and immune functions of lung cancer and pulmonary ground-glass attenuation. Eur Rev Med Pharmacol Sci, 2017, 21(18): 4098-4103.
12.	牛涛, 周逢海. 炎症与肿瘤微环境. 中南大学学报(医学版), 2023, 48(12): 1899-1913.
13.	Yanagawa J, Tran LM, Salehi-Rad R, et al. Single-cell characterization of pulmonary nodules implicates suppression of immunosurveillance across early stages of lung adenocarcinoma. Cancer Res, 2023, 83(19): 3305-3319.
14.	Hu X, Estecio MR, Chen RZ, et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun, 2021, 12(1): 687.
15.	李瑞琴, 金艳, 李伟, 等. 桂附地黄丸抗大鼠肺纤维化的作用及对外周血T淋巴细胞亚群的影响. 中华中医药学刊, 2016, 34(12): 2938-2940.
16.	朱德兵. 肺泡灌洗液中T淋巴细胞在早期周围型肺癌的诊断价值研究. 昆明医科大学, 2022.
17.	Laddha AP, Kulkarni YA. VEGF and FGF-2: promising targets for the treatment of respiratory disorders. Respir Med, 2019, 156: 33-46.
18.	Frezzetti D, Gallo M, Maiello MR, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets, 2017, 21(10): 959-966.
19.	Seder CW, Kubasiak JC, Pithadia R, et al. Angiogenesis biomarkers may be useful in the management of patients with indeterminate pulmonary nodules. Ann Thorac Surg, 2015, 100(2): 429-436.
20.	吕春歌. 血管内皮生长因子C联合CEA、CA199检测对肺孤立性结节的临床鉴别诊断价值. 河南外科学杂志, 2022, 28(6): 48-50.
21.	Wang X, Leader JK, Wang R, et al. Vasculature surrounding a nodule: a novel lung cancer biomarker. Lung Cancer, 2017, 114: 38-43.
22.	Ye S, Chen X, Yao Y, et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: a large-scale, multicenter study. Sci Rep, 2019, 9(1): 2652.
23.	李莎, 惠开元, 孙文, 等. 硫氧还蛋白还原酶在肺癌临床检测中应用. 临床军医杂志, 2020, 48(12): 1415-1417.
24.	居冠军, 施民新, 樊怿辉, 等. 胸部CT联合硫氧还蛋白还原酶检测对孤立性肺结节良恶性的诊断价值. 交通医学, 2023, 37(4): 397-399.
25.	卜亚伟. 硫氧还蛋白还原酶1(TrxR1)筛查早期非小细胞肺癌的临床研究. 河北医科大学, 2020.
26.	丁薇, 王保兰, 李朋玲. 硫氧还蛋白还原酶联合肺癌标志物对肺结节良恶性的诊断意义. 中华肺部疾病杂志(电子版), 2022, 15(5): 685-687.
27.	张国庆, 焦顺昌. 新型肿瘤增殖指标―血清胸苷激酶1的临床应用. 现代肿瘤医学, 2012, 20(8): 1743-1745.
28.	Chen ZH. Serological Thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35, 365 people, using a sensitive chemiluminescent dot blot assay. Sensors (Basel), 2011, 11(12): 11064-11080.
29.	周家田. 血清TK1、CEA、CYFRA21-1联合胸部CT特征在肺结节诊断中的临床价值. 成都医学院, 2020.
30.	金蒙蒙, 叶元滋, 陈梅莉, 等. 肺癌患者血清胸苷激酶1的表达及其临床意义. 实用医学杂志, 2015, 31(3): 413-416.
31.	Alegre MM, Weyant MJ, Bennett DT, et al. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer. Anticancer Res, 2014, 34(5): 2145-2151.
32.	刘亚杰, 马晓波. 肿瘤标志物GSTP1、CYFRA21-1及SCC-Ag对非小细胞肺癌的预后评估价值. 中国现代医学杂志, 2020, 30(14): 42-46.
33.	冯小玲, 陈红梅, 成军霞, 等. 血清NSE、CYFRA21-1、SCC水平联合CT灌注成像对肺结节良恶性病变的诊断价值. 标记免疫分析与临床, 2020, 27(9): 1551-1555,1619.
34.	杨金生, 杜晚楠, 王景升. 多层螺旋CT联合肿瘤标志物对孤立肺结节的诊断价值. 中国卫生工程学, 2023, 22(1): 101-102,106.
35.	万辉, 高美玲, 林洁, 等. 不同类型的肺部磨玻璃结节患者术前免疫炎症指标和癌胚抗原的比较. 温州医科大学学报, 2022, 52(7): 557-561.
36.	Zhong S, Golpon H, Zardo P, et al. Mirnas in lung cancer. a systematic review identifies predictive and prognostic mirna candidates for precision medicine in lung cancer. Transl Res, 2021, 230: 164-196.
37.	Sun ZQ, Shi K, Yang SX, et al. Effect of exosomal mirna on cancer biology and clinical applications. Mol Cancer, 2018, 17(1): 147.
38.	Zhang JT, Qin H, Man Cheung FK, et al. Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules. J Extracell Vesicles, 2019, 8(1): 1663666.
39.	朱海龙. 低剂量螺旋CT联合血浆miR-200b、miR-200c检查鉴别诊断良恶性肺结节的价值. 中国疗养医学, 2022, 31(10): 1109-1112.
40.	程薪樾, 鲍文华, 王晓, 等. 血清miRNA-21检测对肺结节研究的诊断价值. 齐齐哈尔医学院学报, 2021, 42(7): 553-556.
41.	Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell, 2016, 164(1-2): 57-68.
42.	Chen N, Li G, Li H, et al. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer. Cell Mol Biol (Noisy-le-grand). 2020, 66(5): 208-213.
43.	Tao R, Cao W, Zhu F, et al. Liquid biopsies to distinguish malignant from benign pulmonary nodules. Thorac Cancer, 2021, 12(11): 1647-1655.
44.	Szpechcinski A, Rudzinski P, Kupis W, et al. Plasma Cell-free DNA levels and integrity in patients with chest radiological findings nsclc versus benign lung nodules. Cancer Lett, 2016, 374(2): 202-207.
45.	Gao H, Yang J, He L, et al. The diagnostic potential of SHOX2 and RASSF1A DNA methylation in early lung adenocarcinoma. Front Oncol, 2022, 12: 849024.
46.	杨敬平, 杨俊俊, 周婵, 等. 肺泡灌洗液在肺癌早期诊断方面的研究进展. 中华肺部疾病杂志(电子版), 2020, 13(1): 97-99.
47.	Zhang C, Yu W, Wang L, et al. DNA Methylation aAnalysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis. J Cancer, 2017, 8(17): 3585-3591.
48.	杨敬平. 肺泡灌洗液中SHOX2、RASSF1A甲基化及端粒酶活性检测对肺结节良恶性鉴别诊断价值初探. 大连医科大学, 2020.
49.	彭达明. 胸部低剂量CT在肺结节中的诊断效果. 现代医学与健康研究电子杂志, 2023, 7(22): 94-96.
50.	於婧婧, 方金忠, 张文奇, 等. CT各征象对肺磨玻璃结节浸润性及浸润程度的鉴别价值. 全科医学临床与教育, 2023, 21(12): 1092-1095.
51.	Schreuder A, Scholten ET, van Ginneken B, et al. Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice? Transl Lung Cancer Res, 2021, 10(5): 2378-2388.
52.	石逸秋, 沈雨雯, 刘可夫. 基于人工智能的CT肺结节评估的研究进展. 临床放射学杂志, 2024, 43(3): 476-479.
53.	石逸秋, 沈雨雯, 陈劼, 等. CT定量参数预测肺磨玻璃结节病理类型的价值. 中国肺癌杂志, 2024, 27(2): 118-125.
54.	王志平, 郭伟, 真德智. 低剂量胸部CT在肺结节及早期肺癌筛查中的应用. 临床放射学杂志, 2022, 41(7): 1298-1302.
55.	朱俊辉, 李思叶, 黄子康, 等. (18)F-FDG PET/CT原发灶摄取相对值及代谢参数对NSCLC纵隔淋巴结转移的预测价值. 临床放射学杂志, 2023, 42(10): 1584-1589.
56.	邱钱赛, 冯峰, 石健, 等. 18F-FDG PET/CT影像组学鉴别良、恶性高代谢孤立性肺结节. 中国医学影像学杂志, 2022, 30(11): 1136-1142.
57.	Salihoğlu YS, Uslu Erdemir R, Aydur Püren B, et al. Diagnostic performance of machine learning models based on 18F-FDG PET/CT radiomic features in the classification of solitary pulmonary nodules. Mol Imaging Radionucl Ther, 2022, 31(2): 82-88.
58.	江叶海, 蒲豆豆, 于楠. 基于磁共振成像的影像组学在肺癌中的研究进展. 磁共振成像, 2023, 14(7): 166-170.
59.	Burris NS, Johnson KM, Larson PE, et al. Detection of small pulmonary nodules with ultrashort echo time sequences in oncology patients by using a PET/MR system. Radiology, 2016, 278(1): 239-246.
60.	江建芹, 崔磊, 胡春洪, 等. 胸部MR在肺癌筛查及肺结节随诊中的研究. 放射学实践, 2022, 37(2): 274-280.
61.	Liu H, Chen R, Tong C, Liang XW. MRI versus CT for the detection of pulmonary nodules: a meta-analysis. Medicine (Baltimore), 2021, 100(42): e27270.
62.	黄玉阳, 赵春玲, 张冰璐, 等. FUT7甲基化联合CT影像特征预测肺腺癌发生风险的列线图模型. 中国呼吸与危重监护杂志, 2024, 23(2): 95-104.
63.	何花, 胡文滕, 蔺瑞江, 等. CT特征联合肿瘤标志物预测肺磨玻璃结节肿瘤浸润性的回顾性队列研究. 中国胸心血管外科临床杂志, 2022, 29(9): 1113-1119.
64.	Zhang W, Duan X, Zhang Z, et al. Combination of CT and telomerase+ circulating tumor cells improves diagnosis of small pulmonary nodules. JCI Insight, 2021, 6(11): e148182.
65.	Zyla J, Marczyk M, Prazuch W, et al. Combining low-dose computer-tomography-based radiomics and serum metabolomics for diagnosis of malignant nodules in participants of lung cancer screening studies. Biomolecules, 2023, 14(1): 44.
66.	Xu S, Ge J, Liu X, et al. The predictive value of chest computed tomography images, tumor markers, and metabolomics in the identification of benign and malignant pulmonary nodules. J Thorac Dis, 2023, 15(5): 2668-2679.
67.	吴少虹, 郭莉莉. 影像组学在肺癌中的应用. 放射学实践, 2023, 38(6): 778-782.
68.	Marmor HN, Jackson L, Gawel S, et al. Improving malignancy risk prediction of indeterminate pulmonary nodules with imaging features and biomarkers. Clin Chim Acta, 2022, 534: 106-114.
69.	Patel N, Xu W, Deng Y, et al. Cross-scale integration of nano-sized extracellular vesicle-based biomarker and radiomics features for predicting suspected sub-solid pulmonary nodules. J Biomed Nanotechnol, 2021, 17(6): 1109-1122.
70.	赵佳佳, 邢媛媛, 杨静, 等. 超级迭代PET/CT定量参数联合癌胚抗原鉴别良、恶性孤立性肺结节. 中国医学影像技术, 2022, 38(10): 1497-1502.
71.	李大鹏, 于波, 吴明英, 等. 磁共振3D-VIBE序列联合生化指标水平检测在肺结节诊断研究. 浙江创伤外科, 2022, 27(4): 804-806.

1. 中华医学会呼吸病学分会肺癌学组, 中国肺癌防治联盟专家组. 肺结节诊治中国专家共识(2018年版). 中华结核和呼吸杂志, 2018, 41(10): 763-771.
2. Liang X, Kong Y, Shang H, et al. Computed tomography findings, associated factors, and management of pulmonary nodules in 54, 326 healthy individuals. J Cancer Res Ther, 2022, 18(7): 2041-2048.
3. 谭双平, 张彤, 祖江林, 等. 深度学习驱动的CT影像肺结节检测: 挑战、进展和展望. 中国医疗器械杂志, 2023, 47(2): 163-172.
4. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood), 2018, 243(3): 213-221.
5. Shen C, Wu Q, Xia Q, et al. Establishment of a malignancy and benignancy prediction model of sub-centimeter pulmonary ground-glass nodules based on the inflammation-cancer transformation theory. Front Med (Lausanne), 2022, 9: 1007589.
6. Husari A, Hashem Y, Zaatari G, et al. Pomegranate juice prevents the formation of lung nodules secondary to chronic cigarette smoke exposure in an animal model. Oxid Med Cell Longev, 2017, 2017: 6063201.
7. Zhang Y, Liu Y, Wang J, et al. Atractylenolide II inhibits tumor-associated macrophages (TAMs)-induced lung cancer cell metastasis. Immunopharmacol Immunotoxicol, 2022, 44(2): 227-237.
8. Tian T, Lu J, Zhao W, et al. Associations of systemic inflammation markers with identification of pulmonary nodule and incident lung cancer in Chinese population. Cancer Med, 2022, 11(12): 2482-2491.
9. 姜文军. 血清中IL-15、IL-6、TNF-β、IFN-γ、CRP、Beclin1与早期肺腺癌关系的研究. 安徽医科大学, 2022.
10. Daly S, Rinewalt D, Fhied C, et al. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol, 2013, 8(1): 31-36.
11. Liu CY, Xie WG, Wu S, et al. A comparative study on inflammatory factors and immune functions of lung cancer and pulmonary ground-glass attenuation. Eur Rev Med Pharmacol Sci, 2017, 21(18): 4098-4103.
12. 牛涛, 周逢海. 炎症与肿瘤微环境. 中南大学学报(医学版), 2023, 48(12): 1899-1913.
13. Yanagawa J, Tran LM, Salehi-Rad R, et al. Single-cell characterization of pulmonary nodules implicates suppression of immunosurveillance across early stages of lung adenocarcinoma. Cancer Res, 2023, 83(19): 3305-3319.
14. Hu X, Estecio MR, Chen RZ, et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun, 2021, 12(1): 687.
15. 李瑞琴, 金艳, 李伟, 等. 桂附地黄丸抗大鼠肺纤维化的作用及对外周血T淋巴细胞亚群的影响. 中华中医药学刊, 2016, 34(12): 2938-2940.
16. 朱德兵. 肺泡灌洗液中T淋巴细胞在早期周围型肺癌的诊断价值研究. 昆明医科大学, 2022.
17. Laddha AP, Kulkarni YA. VEGF and FGF-2: promising targets for the treatment of respiratory disorders. Respir Med, 2019, 156: 33-46.
18. Frezzetti D, Gallo M, Maiello MR, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets, 2017, 21(10): 959-966.
19. Seder CW, Kubasiak JC, Pithadia R, et al. Angiogenesis biomarkers may be useful in the management of patients with indeterminate pulmonary nodules. Ann Thorac Surg, 2015, 100(2): 429-436.
20. 吕春歌. 血管内皮生长因子C联合CEA、CA199检测对肺孤立性结节的临床鉴别诊断价值. 河南外科学杂志, 2022, 28(6): 48-50.
21. Wang X, Leader JK, Wang R, et al. Vasculature surrounding a nodule: a novel lung cancer biomarker. Lung Cancer, 2017, 114: 38-43.
22. Ye S, Chen X, Yao Y, et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: a large-scale, multicenter study. Sci Rep, 2019, 9(1): 2652.
23. 李莎, 惠开元, 孙文, 等. 硫氧还蛋白还原酶在肺癌临床检测中应用. 临床军医杂志, 2020, 48(12): 1415-1417.
24. 居冠军, 施民新, 樊怿辉, 等. 胸部CT联合硫氧还蛋白还原酶检测对孤立性肺结节良恶性的诊断价值. 交通医学, 2023, 37(4): 397-399.
25. 卜亚伟. 硫氧还蛋白还原酶1(TrxR1)筛查早期非小细胞肺癌的临床研究. 河北医科大学, 2020.
26. 丁薇, 王保兰, 李朋玲. 硫氧还蛋白还原酶联合肺癌标志物对肺结节良恶性的诊断意义. 中华肺部疾病杂志(电子版), 2022, 15(5): 685-687.
27. 张国庆, 焦顺昌. 新型肿瘤增殖指标―血清胸苷激酶1的临床应用. 现代肿瘤医学, 2012, 20(8): 1743-1745.
28. Chen ZH. Serological Thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35, 365 people, using a sensitive chemiluminescent dot blot assay. Sensors (Basel), 2011, 11(12): 11064-11080.
29. 周家田. 血清TK1、CEA、CYFRA21-1联合胸部CT特征在肺结节诊断中的临床价值. 成都医学院, 2020.
30. 金蒙蒙, 叶元滋, 陈梅莉, 等. 肺癌患者血清胸苷激酶1的表达及其临床意义. 实用医学杂志, 2015, 31(3): 413-416.
31. Alegre MM, Weyant MJ, Bennett DT, et al. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer. Anticancer Res, 2014, 34(5): 2145-2151.
32. 刘亚杰, 马晓波. 肿瘤标志物GSTP1、CYFRA21-1及SCC-Ag对非小细胞肺癌的预后评估价值. 中国现代医学杂志, 2020, 30(14): 42-46.
33. 冯小玲, 陈红梅, 成军霞, 等. 血清NSE、CYFRA21-1、SCC水平联合CT灌注成像对肺结节良恶性病变的诊断价值. 标记免疫分析与临床, 2020, 27(9): 1551-1555,1619.
34. 杨金生, 杜晚楠, 王景升. 多层螺旋CT联合肿瘤标志物对孤立肺结节的诊断价值. 中国卫生工程学, 2023, 22(1): 101-102,106.
35. 万辉, 高美玲, 林洁, 等. 不同类型的肺部磨玻璃结节患者术前免疫炎症指标和癌胚抗原的比较. 温州医科大学学报, 2022, 52(7): 557-561.
36. Zhong S, Golpon H, Zardo P, et al. Mirnas in lung cancer. a systematic review identifies predictive and prognostic mirna candidates for precision medicine in lung cancer. Transl Res, 2021, 230: 164-196.
37. Sun ZQ, Shi K, Yang SX, et al. Effect of exosomal mirna on cancer biology and clinical applications. Mol Cancer, 2018, 17(1): 147.
38. Zhang JT, Qin H, Man Cheung FK, et al. Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules. J Extracell Vesicles, 2019, 8(1): 1663666.
39. 朱海龙. 低剂量螺旋CT联合血浆miR-200b、miR-200c检查鉴别诊断良恶性肺结节的价值. 中国疗养医学, 2022, 31(10): 1109-1112.
40. 程薪樾, 鲍文华, 王晓, 等. 血清miRNA-21检测对肺结节研究的诊断价值. 齐齐哈尔医学院学报, 2021, 42(7): 553-556.
41. Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell, 2016, 164(1-2): 57-68.
42. Chen N, Li G, Li H, et al. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer. Cell Mol Biol (Noisy-le-grand). 2020, 66(5): 208-213.
43. Tao R, Cao W, Zhu F, et al. Liquid biopsies to distinguish malignant from benign pulmonary nodules. Thorac Cancer, 2021, 12(11): 1647-1655.
44. Szpechcinski A, Rudzinski P, Kupis W, et al. Plasma Cell-free DNA levels and integrity in patients with chest radiological findings nsclc versus benign lung nodules. Cancer Lett, 2016, 374(2): 202-207.
45. Gao H, Yang J, He L, et al. The diagnostic potential of SHOX2 and RASSF1A DNA methylation in early lung adenocarcinoma. Front Oncol, 2022, 12: 849024.
46. 杨敬平, 杨俊俊, 周婵, 等. 肺泡灌洗液在肺癌早期诊断方面的研究进展. 中华肺部疾病杂志(电子版), 2020, 13(1): 97-99.
47. Zhang C, Yu W, Wang L, et al. DNA Methylation aAnalysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis. J Cancer, 2017, 8(17): 3585-3591.
48. 杨敬平. 肺泡灌洗液中SHOX2、RASSF1A甲基化及端粒酶活性检测对肺结节良恶性鉴别诊断价值初探. 大连医科大学, 2020.
49. 彭达明. 胸部低剂量CT在肺结节中的诊断效果. 现代医学与健康研究电子杂志, 2023, 7(22): 94-96.
50. 於婧婧, 方金忠, 张文奇, 等. CT各征象对肺磨玻璃结节浸润性及浸润程度的鉴别价值. 全科医学临床与教育, 2023, 21(12): 1092-1095.
51. Schreuder A, Scholten ET, van Ginneken B, et al. Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice? Transl Lung Cancer Res, 2021, 10(5): 2378-2388.
52. 石逸秋, 沈雨雯, 刘可夫. 基于人工智能的CT肺结节评估的研究进展. 临床放射学杂志, 2024, 43(3): 476-479.
53. 石逸秋, 沈雨雯, 陈劼, 等. CT定量参数预测肺磨玻璃结节病理类型的价值. 中国肺癌杂志, 2024, 27(2): 118-125.
54. 王志平, 郭伟, 真德智. 低剂量胸部CT在肺结节及早期肺癌筛查中的应用. 临床放射学杂志, 2022, 41(7): 1298-1302.
55. 朱俊辉, 李思叶, 黄子康, 等. (18)F-FDG PET/CT原发灶摄取相对值及代谢参数对NSCLC纵隔淋巴结转移的预测价值. 临床放射学杂志, 2023, 42(10): 1584-1589.
56. 邱钱赛, 冯峰, 石健, 等. 18F-FDG PET/CT影像组学鉴别良、恶性高代谢孤立性肺结节. 中国医学影像学杂志, 2022, 30(11): 1136-1142.
57. Salihoğlu YS, Uslu Erdemir R, Aydur Püren B, et al. Diagnostic performance of machine learning models based on 18F-FDG PET/CT radiomic features in the classification of solitary pulmonary nodules. Mol Imaging Radionucl Ther, 2022, 31(2): 82-88.
58. 江叶海, 蒲豆豆, 于楠. 基于磁共振成像的影像组学在肺癌中的研究进展. 磁共振成像, 2023, 14(7): 166-170.
59. Burris NS, Johnson KM, Larson PE, et al. Detection of small pulmonary nodules with ultrashort echo time sequences in oncology patients by using a PET/MR system. Radiology, 2016, 278(1): 239-246.
60. 江建芹, 崔磊, 胡春洪, 等. 胸部MR在肺癌筛查及肺结节随诊中的研究. 放射学实践, 2022, 37(2): 274-280.
61. Liu H, Chen R, Tong C, Liang XW. MRI versus CT for the detection of pulmonary nodules: a meta-analysis. Medicine (Baltimore), 2021, 100(42): e27270.
62. 黄玉阳, 赵春玲, 张冰璐, 等. FUT7甲基化联合CT影像特征预测肺腺癌发生风险的列线图模型. 中国呼吸与危重监护杂志, 2024, 23(2): 95-104.
63. 何花, 胡文滕, 蔺瑞江, 等. CT特征联合肿瘤标志物预测肺磨玻璃结节肿瘤浸润性的回顾性队列研究. 中国胸心血管外科临床杂志, 2022, 29(9): 1113-1119.
64. Zhang W, Duan X, Zhang Z, et al. Combination of CT and telomerase+ circulating tumor cells improves diagnosis of small pulmonary nodules. JCI Insight, 2021, 6(11): e148182.
65. Zyla J, Marczyk M, Prazuch W, et al. Combining low-dose computer-tomography-based radiomics and serum metabolomics for diagnosis of malignant nodules in participants of lung cancer screening studies. Biomolecules, 2023, 14(1): 44.
66. Xu S, Ge J, Liu X, et al. The predictive value of chest computed tomography images, tumor markers, and metabolomics in the identification of benign and malignant pulmonary nodules. J Thorac Dis, 2023, 15(5): 2668-2679.
67. 吴少虹, 郭莉莉. 影像组学在肺癌中的应用. 放射学实践, 2023, 38(6): 778-782.
68. Marmor HN, Jackson L, Gawel S, et al. Improving malignancy risk prediction of indeterminate pulmonary nodules with imaging features and biomarkers. Clin Chim Acta, 2022, 534: 106-114.
69. Patel N, Xu W, Deng Y, et al. Cross-scale integration of nano-sized extracellular vesicle-based biomarker and radiomics features for predicting suspected sub-solid pulmonary nodules. J Biomed Nanotechnol, 2021, 17(6): 1109-1122.
70. 赵佳佳, 邢媛媛, 杨静, 等. 超级迭代PET/CT定量参数联合癌胚抗原鉴别良、恶性孤立性肺结节. 中国医学影像技术, 2022, 38(10): 1497-1502.
71. 李大鹏, 于波, 吴明英, 等. 磁共振3D-VIBE序列联合生化指标水平检测在肺结节诊断研究. 浙江创伤外科, 2022, 27(4): 804-806.

Previous Article
胸部CT表现为反晕征的鹦鹉热衣原体肺炎两例报告
Next Article
支气管循环生理及其在不同肺疾病中的病理变化

Chinese Journal of Respiratory and Critical Care Medicine

生物标志物联合影像学在肺结节诊断中的研究进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content